Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy.

Objectives: Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.
Data Description: Liver specimens were obtained from 11 dogs with HCC and four dogs without HCC. We performed RNA seq using the mRNA extracted from the specimens. Differentially expressed genes (DEGs) between canine HCC and normal liver were explored based on previously reported molecular-targeted agents for human tumours. PARP3, DNMT1, FGF19, FGF23, and RET DEGs were upregulated, whereas KIT, FGFR2, and FGF21 DEGs were downregulated.
Competing Interests: Declarations. Ethics approval and consent to participate: Informed consent for sample collection of HCC in this study was obtained from all clients at first examination of their dogs. The normal liver was a piece of liver tissue that had been collected and cryopreserved in another project that was properly conducted according to the Guidelines of Animal Care and Use in Osaka Metropolitan University. Consent for publication: Informed consent for publication of HCC in this study was obtained from all clients at first examination of their dogs. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)